Hiroto Yamamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiroto Yamamoto has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Hiroyuki Sugihara
Department of Pathology, Shiga University of Medical Science
2 shared publicationsKen-Ichi Mukaisho
Department of Pathology, Shiga University of Medical Science
2 shared publicationsKenzo Okumura
Department of Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan University
2 shared publicationsShinji Asano
Department of Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan University
2 shared publicationsTakanori Hattori
Department of Pathology, Shiga University of Medical Science
2 shared publications- Akihiko Yokota
Department of Gastroenterology Shimada Municipal Hospital Shimada Japan
1 shared publication
Latest Publications
- Open Access
- 24 May 2021
- Published by Wiley in Clinical Case Reports
- Vol. 9 (5) , e04254
Gastric perforation caused by secondary systemic amyloidosis
Amyloid A amyloidosis secondary to chronic inflammation involves systemic organs and tissues, including the gastrointestinal tract. In the present case, massive amyloid deposit caused gastric perforation. IgM co‐deposition in the glomeruli was another finding of note.
- 24 May 2021
- Published by Wiley in Clinical Case Reports
- Vol. 9 (5) , e04254
Open AccessGastric perforation caused by secondary systemic amyloidosis
Amyloid A amyloidosis secondary to chronic inflammation involves systemic organs and tissues, including the gastrointestinal tract. In the present case, massive amyloid deposit caused gastric perforation. IgM co‐deposition in the glomeruli was another finding of note.
- 1 January 2011
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 34 (3) , 324-329
Down-Regulation of FXYD3 Is Induced by Transforming Growth Factor-.BETA. Signaling via ZEB1/.DELTA.EF1 in Human Mammary Epithelial Cells
FXYD3, a regulator of Na, K-ATPase, was identified as an mRNA overexpressed in murine breast cancers induced by neu oncogene, which had inactivated transforming growth factor (TGF)-β signaling due to the defect of TGF-β receptor I (TβRI) expression. To elucidate whether the expression of FXYD3 mRNA was regulated by TGF-β signaling, we used a normal human mammary epithelial cell line, MCF-10A which responds to TGF-β and tumor necrosis factor (TNF)-α, followed by induction of epithelial-to-mesenchymal transition (EMT). Here, we showed that FXYD3 at plasma membrane in epithelial state of MCF-10A cells was decreased by treatment of TGF-β and TNF-α. The repression of FXYD3 mRNA induced by TGF-β and TNF-α in MCF-10A cells was abolished by TβRI inhibitor or Smad3 inhibitor, but not by small interfering RNA (siRNA) for Smad2. In addition, expression level of FXYD3 mRNA was up-regulated by the silencing of ZEB1/δEF1 transcriptional repressor which was a down-stream target gene of TGF-β and an inducer of EMT. On the other hand, expression level and cellular localization of E-cadherin and N-cadherin were not changed by siRNA for FXYD3 in MCF-10A and human breast cancer MCF-7 cells. These results suggest that FXYD3 is a target gene of TGF-β signaling through ZEB1/δEF1, but is not directly involved in EMT.
- 1 January 2011
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 34 (3) , 324-329
Down-Regulation of FXYD3 Is Induced by Transforming Growth Factor-.BETA. Signaling via ZEB1/.DELTA.EF1 in Human Mammary Epithelial Cells
FXYD3, a regulator of Na, K-ATPase, was identified as an mRNA overexpressed in murine breast cancers induced by neu oncogene, which had inactivated transforming growth factor (TGF)-β signaling due to the defect of TGF-β receptor I (TβRI) expression. To elucidate whether the expression of FXYD3 mRNA was regulated by TGF-β signaling, we used a normal human mammary epithelial cell line, MCF-10A which responds to TGF-β and tumor necrosis factor (TNF)-α, followed by induction of epithelial-to-mesenchymal transition (EMT). Here, we showed that FXYD3 at plasma membrane in epithelial state of MCF-10A cells was decreased by treatment of TGF-β and TNF-α. The repression of FXYD3 mRNA induced by TGF-β and TNF-α in MCF-10A cells was abolished by TβRI inhibitor or Smad3 inhibitor, but not by small interfering RNA (siRNA) for Smad2. In addition, expression level of FXYD3 mRNA was up-regulated by the silencing of ZEB1/δEF1 transcriptional repressor which was a down-stream target gene of TGF-β and an inducer of EMT. On the other hand, expression level and cellular localization of E-cadherin and N-cadherin were not changed by siRNA for FXYD3 in MCF-10A and human breast cancer MCF-7 cells. These results suggest that FXYD3 is a target gene of TGF-β signaling through ZEB1/δEF1, but is not directly involved in EMT.
- Open Access
- 1 January 2009
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 32 (7) , 1148-1154
FXYD3 Protein Involved in Tumor Cell Proliferation Is Overproduced in Human Breast Cancer Tissues
FXYD3, also known as Mat-8 (Mammary tumor 8 kDa), is one of mRNAs highly expressed in mouse and human breast cancers. Here, we newly found that FXYD3 protein was also overexpressed in human breast cancer specimens; invasive ductal carcinomas and intra-ductal carcinomas, whereas its expression was low in benign lesion specimens; mastopathy, fibroadenoma and phyllodes tumors. Although human FXYD3 has two isoforms (shorter FXYD3a and longer FXYD3b), there have been no reports in which these two mRNAs were separately quantified. Here, we found that FXYD3a mRNA is a major transcript product expressed in human normal tissues as well as in breast, colon, stomach and pancreas cancer cell lines. In addition, expression level of FXYD3b was much lower than that of FXYD3a in these cancer cell lines. Cell proliferation rate of MCF-7 breast cancer cell line was drastically decreased when FXYD3a and 3b mRNAs were suppressed by the small interfering RNA. These results suggest that FXYD3a protein is highly expressed in breast cancers, and responsible for cancer cell proliferation.
- 1 January 2009
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 32 (7) , 1148-1154
Open AccessFXYD3 Protein Involved in Tumor Cell Proliferation Is Overproduced in Human Breast Cancer Tissues
FXYD3, also known as Mat-8 (Mammary tumor 8 kDa), is one of mRNAs highly expressed in mouse and human breast cancers. Here, we newly found that FXYD3 protein was also overexpressed in human breast cancer specimens; invasive ductal carcinomas and intra-ductal carcinomas, whereas its expression was low in benign lesion specimens; mastopathy, fibroadenoma and phyllodes tumors. Although human FXYD3 has two isoforms (shorter FXYD3a and longer FXYD3b), there have been no reports in which these two mRNAs were separately quantified. Here, we found that FXYD3a mRNA is a major transcript product expressed in human normal tissues as well as in breast, colon, stomach and pancreas cancer cell lines. In addition, expression level of FXYD3b was much lower than that of FXYD3a in these cancer cell lines. Cell proliferation rate of MCF-7 breast cancer cell line was drastically decreased when FXYD3a and 3b mRNAs were suppressed by the small interfering RNA. These results suggest that FXYD3a protein is highly expressed in breast cancers, and responsible for cancer cell proliferation.
- Open Access
- 1 April 2007
- Published by Wiley in The FASEB Journal
- Vol. 21 (5) , A535
Down‐regulation of FXYD3 protein, a regulator of Na + ,K + ‐ATPase, in human colorectal cancers
The FXYD family proteins are small proteins which contain a single transmembrane domain, and the □gFXYD (Phe‐Xaa‐Tyr‐Asp) motif□h in the ectodomain. They associate with the Na + ,K + ‐ATPase to modulate its function. Among seven members of the FXYD proteins, the FXYD3 (Mat‐8) associates with the Na + ,K + ‐ATPase and decreases its affinity for Na + and K + . The FXYD3 was also reported to be involved in cell proliferation and tumorigenesis. Here, we studied the mRNA expression level of FXYD3 in human cultured cell lines, and normal tissues by the real‐time PCR, and found that the mRNA was highly expressed in a breast cancer cell line, MCF‐7 and a pancreatic cancer cell line, T3M‐4. The mRNA expression level of FXYD3 was highest in colons. We also studied the protein expression of FXYD3 by using a monoclonal antibody against human FXYD3. The FXYD3 protein with a molecular mass of 13 kDa was also highly expressed in human colon. It is interesting that the FXYD3 protein was down‐regulated in human colorectal cancers compared with the surrounding normal mucosae. This down‐regulation of the FXYD3 seems to correspond with the down‐regulation of Na + ,K + ‐ATPase α1‐subunit in the same colorectal cancers.
- 1 April 2007
- Published by Wiley in The FASEB Journal
- Vol. 21 (5) , A535
Open AccessDown‐regulation of FXYD3 protein, a regulator of Na + ,K + ‐ATPase, in human colorectal cancers
The FXYD family proteins are small proteins which contain a single transmembrane domain, and the □gFXYD (Phe‐Xaa‐Tyr‐Asp) motif□h in the ectodomain. They associate with the Na + ,K + ‐ATPase to modulate its function. Among seven members of the FXYD proteins, the FXYD3 (Mat‐8) associates with the Na + ,K + ‐ATPase and decreases its affinity for Na + and K + . The FXYD3 was also reported to be involved in cell proliferation and tumorigenesis. Here, we studied the mRNA expression level of FXYD3 in human cultured cell lines, and normal tissues by the real‐time PCR, and found that the mRNA was highly expressed in a breast cancer cell line, MCF‐7 and a pancreatic cancer cell line, T3M‐4. The mRNA expression level of FXYD3 was highest in colons. We also studied the protein expression of FXYD3 by using a monoclonal antibody against human FXYD3. The FXYD3 protein with a molecular mass of 13 kDa was also highly expressed in human colon. It is interesting that the FXYD3 protein was down‐regulated in human colorectal cancers compared with the surrounding normal mucosae. This down‐regulation of the FXYD3 seems to correspond with the down‐regulation of Na + ,K + ‐ATPase α1‐subunit in the same colorectal cancers.